2. Read chapters 5 through 10 and chapters 12 through 14 and other sources.

Make a graph of column F in the isometric weights spreadsheet (50 lb column). What part of the typical processing of EMG does the signal in the F column look like?

- *S5: Discuss appropriate and informed career management choices and entrepreneurial issues* - Consider including a section on the practical applications of studying flaviviruses and pseudotyped viruses in terms of career opportunities and entrepreneurship.

1. Enzymes: Biological Engineering to Support Bioreactors and Biosensors Enzymes in Weapons Production and Weapons Defense - • Enzymes in Weapons in Bioremediation - a report of at least 2 pages in length (1.5 spacing) with citations (pictures and diagrams are welcome and accepted (and improve your grade) but do not contribute to the 2 pages of report). Please include at least three examples with your general topic description. References

2nd submission It should be exactly like this How does this relate to business and entrepreneurship plus career management? Which businesses have seen an opportunity so far? smartCells go Cord blood and adult stem cell storage company based in the UK offering package options for approximately 2000 plus c100 per year storage fee. BlueRock Therapeutics A joint venture between Bayer and Versant Ventures who have both invested a combined $225 million dollars. The company mainly focuses on technologies around cardiovascular, neurological and autoimmune applications currently. What careers and jobs are available in this sector? Bioinformatics Specialist to T Novo Foundatier for Stem and Protein Research (CP Location tom) Public Engagement Officer Location London, United Kingdom Organisation Centre for Stem Cells and Regenerative Medicine (CSCRM) Laboratory Technician Location: Copenhagen, Denmark Organisation: DanStem What is the industry worth? The global stem cell market size was estimated to be at 56.87 billion in 2016. Transparency Market Research estimate that the global market will be worth $270.5 billion by 2025 research for the job and business/nIt's a group presentation my section is employability I will talk about the jobs and business and how it's related to the job.I will be talking about how we apply this knowledge into real world ... And then I will talk about the jobs and the difference between them and I will say why would I go for this or that job... and then I will talk about the business the example of the business... Career Management Chofces b Job 2 Why لاد Job ل Why Add referebces abd if there any photo of the company logo Idea

2. Read chapters 5 through 10 and chapters 12 through 14 and other sources. To research the predominant bioengineering careers in the past, those which currently comprise the market and what is forecast for the future. What are the major career options, and where is this going in the future? References

3. Use all resources available to find and describe the biomedical engineering code of ethics, and compare it to the Hippocratic Oath. (Minimum length - approx. 1 page) References

1st submission Student needs 2 Jobs and 2 Business (companies names) Based on instructions of previous work topic Poster Title New strategies to produce pseudotyped viruses to study entry of Flaviviruses Synopsis A pseudotyped virus (PV) is a viral particle harbouring the core structure of one virus and the envelope (Env), the viral protein which interacts with the cellular receptor mediating entry, of a heterologous virus: these PV have been largely employed in gene therapy, serology and virus-host interaction studies. The use of PV is particularly important to study viruses classified as hazard group 3 and 4, as they can be handled at a lower containment level (BSL1/2) and do not require enhanced security, such examples are Ebola and other filoviruses, Lassa fever, Coronaviruses. However, those viruses which assemble within the intracellular membrane systems are particularly difficult to pseudotype, as the incorporation of their Env on the surface of a PV is compromised by the endoplasmic reticulum (ER) retention signal present on their Env. These include viruses which have caused or have the potential to cause an outbreak such as flaviviruses, e.g. Zika virus, Dengue virus and Japanese Encephalitis virus (IEV). Please note: The poster title has been set and the title cannot be changed.

Part I: Multiple Alignment A. Go to the EBI multiple sequence alignment tool page: (http://www.ebi.ac.uk/Tools/msa/) B. Click the "Launch Clustal Omega" link and at step 1 paste the CLUSTAL query from the Week 4 links page into the sequences in any supported format window. C. At step 2, click on "output format" and change it to Pearson/FASTA. Now click "submit" and wait for your job to finish. D. When your alignment job finishes, take a picture of your output and insert it here. E. Now click on the "Phylogenetic Tree" tab. This shows the tree used to construct the alignment. Take a picture of your tree and insert it here. F. You can create much nicer and more useful outputs using Mview. Click on the "Results Viewer" tab and then "View in MView" button. At Step 2 select input format: automatic. At step 3 on the MView submission page you can customize how your alignment is colored and formatted. Take a picture of your Mview output and insert it here. G. Return to the EBI multiple sequence alignment tool page: (http://www.ebi.ac.uk/Tools/msa) Repeat steps B-D, except click "Launch T-Coffee" for part B. H. Click on the "Phylogenetic Tree" tab. This shows the tree used to construct the T-Coffee alignment. Take a picture of your tree and insert it here. I. Now send your alignment to MView. At step 3 on the MView submission page be sure to use the same settings as for the Clustal Omega alignment. Take a picture of your Mview T- Coffee output and insert it here. J. Return to the EBI multiple sequence alignment tool page: (http://www.ebi.ac.uk/Tools/msa) Repeat steps B-D, except click "Launch MAFFT" for part B./nB. K. Click on the "Phylogenetic Tree" tab. This shows the tree used to construct the MAFFT alignment. Take a picture of your tree and insert it here. L. Now send your alignment to MView At step 3 on the MView submission page be sure to use the same settings as for the Clustal Omega alignment. Take a picture of your Mview MAFFT output and insert it here. M. Do you see any differences between the three alignments in the order in which the sequences are listed? N. Do you see any differences between the three alignments in the consensus? O. Do you see any other differences between the three alignments? P. Which alignment program would be most appropriate according to the table included in this week's lecture?/nQ. What other alignment methods might have been appropriate? R. What settings (if any) may have increased the quality of the alignment for ClustalOmega or MAFFT? Part II: Finding motifs A. Why is it useful to find motifs? B. Why might motifs be missed by global alignment programs? C. Why can motifs tell us about a group of proteins? D. Copy the "Clustal query" sequences, then go to the meme website http://meme- suite.org/tools/meme a. Select "classic mode" b. Under "Input the primary sequences" select "type in sequences" and then paste the CLUSTAL query from the Week 4 links page into the sequences under input primary sequences "10" for Maximum number of motifs to find then click the "start search" button. When your job finishes use the link at the top of the page to see your results. 1. How many motifs did it find? 2. Did each sequence have the same motifs in the same order?/nB. Now copy the sequence for gi|1084385 then analyze it with Motif Scan at prosite: http://myhits.isb-sib.ch/cgi-bin/motif scan (make sure you check all of the databases below the sequence window) 1. How many motifs did it find? 2. How many were significant (i.e. had a blue exclamation point)? 3. Were there any differences between the two sites? C. Now copy the sequence for gi|1084385 then analyze it with interproscan http://www.ebi.ac.uk/Tools/pfa/iprscan/ 1. What homologous families does this protein belong to? 2. What motifs did it identify? Were any not previously identified?

Fundamentals of Scientific Inquiry We have discussed science throughout history this term, paying particular attention to the paradigm shifts that occurred as scientists reorganized their data to fit with a model that had greater explanatory power. Research a paradigm shift within a particular field of science that we have not covered in class. Choose a particular scientific field (medicine, geology, biology, microbiology, genetics, physics, anatomy, ecology, astronomy, neuroscience, engineering, etc.) Choose a time in which this field was undergoing a great change in thinking or methodology. Argue for whether or not this time in history was a true paradigm shift, given what you know of Thomas Kuhn's definition. In order to do this, you should examine the differences and similarities between the previous era in this scientific field and the one that came after, with reference to the models and methods used and discoveries made.

Introduction - set the scene; what are we looking at, why is this an issue worth carrying out an audit for? Methods - Imagine you were doing this audit completely yourself, not that we gave you the data. Set out what data was collected in order to carry out the audit, and how you analysed this (note this is not the results of your analysis, but the methods of how to do the analysis). You should probably also set out here what the target is you are aiming for; if you remember we said in the introduction session that a key thing about audits is that you are assessing performance against a set standard, so what is the standard that you are aiming for? Note that we've not told you a set standard you are aiming for, we are looking for you to set a sensible standard. We've given you some clues in the questions we asked you to find answers to: What is the MEAN number of PPI issues over 12 months? What is the MEAN number of alginate issues in the same period? What is the PERCENTAGE of patients on PPIs who are issued >2 alginate antacids in 12 months? Of these points, can you find any indications about how many of these medications patients should be getting prescribed? Are there limits suggested anywhere? Results - This is largely what you generated during the TBL session in answering those 3 questions we gave you. How to present that is up to you. I wouldn't include the entire dataset you were working with as that would just be a massive table which wouldn't be very informative. It may be worth summarising the data by including a table with factors such as the mean and any other points you think may be relevant. Discussion - the results section is where you state what your results are. The discussion is where you consider what your results mean. We asked you analyse the data about PPI and alginate issues over the last 12 months. Relate that to the target you set, how does this compare to the target? Are there any numbers in your analysis too high, or too low? If so, why might this be? Action plan and recommendations - if you identified any problems through your audit of this data, what recommendations can you make to improve the situation? Use an action plan (e.g. SMART action plan) to set out how you would implement any changes. Make sure you include something on how/why this change would help. Word count - Several people asked if the action plan would be included in the word count. If you include it in the main text, then yes, but keep in mind a SMART action plan can easily be formatted as a table and that figures and tables don't count towards the word count. For references, citations in the text usually do count towards the word count but the reference list at the end doesn't. There is a 10% tolerance on the word count, so with a 1000 word limit you'll only get penalties if you go over 1100 words. References - you probably won't need many references for this, certainly fewer than you used in the report, but you still should cite appropriately. For example, in you introduction when you set out the topic and potential problem, you might refer to some published literature on the topic, or a relevant section of the NICE Guidelines. When considering your action plans, perhaps there might be some published literature to support the actions you're taking, showing that these actions have previously worked elsewhere./n 23 Your audit assignment A recent review by the NHS England team found that many patients are being co-prescribed PPIs in addition to alginate antacids when there is no clinical need. • Preliminary data would suggest that on average, practices within the ICS are within the highest quintile (top 20%) of practices throughout the country for co- prescribing PPIs in addition to alginate antacids. Feb 2022 GAVISCON LIQUE GAVISCON GAVISCON GAVISCON MESLE ACTION Healthcare Professional: AUDIT 89 shutterstock.com. 1457661998 AV AVELA ASSIGNMENT BRIEF: You must prepare a 1000 word audit report using the template provided. This is an individual assignment. Your team will be given a dataset, and you can work together on the analysis of this dataset, but the assignment you submit must be your own individual work. It will be processed through a similarity checker (Turltln). Background The national NHS England team have asked Integrated Care Systems (ICSs) to review their drug budget for the current financial year and your ICS has announced several projects in their "Quality, Innovation, Productivity and Prevention" (QIPP) programme for the current financial year. One of the priority areas identified by NHS England has been around management of reflux. Recent data has found that many patients are being co-prescribed Proton Pump Inhibitors (PPIs) in addition to alginate antacids (e.g. Gaviscon®) when there is no clinical need. Preliminary data would suggest that on average, practices within your ICS are within the highest quintile (top 20%) of practices in England for this practice which may be wasteful, or suggest that patients with reflux are inadequately managed. Task 1: Analyse the data All practices within the local ICS have reported on patients who are prescribed PPI and/or alginate antacids within the last 12 months. You have been provided a data set for one of the practices. Complete the following audit activity in class, working with your team to process the data. We anticipate that you will work on this during the TBL workshop (on either 24th or 25th January, depending on your team). You can do the analysis any time, but we recommend making use of these sessions for the analysis as staff will be present to help with any issues. 1. Calculate the mean number of PPI issues in 12 months. 2. Calculate the mean number of alginate antacid issues in 12 months. All practices within the local ICS have reported on patients who are prescribed PPI and/or alginate antacids within the last 12 months. You have been provided a data set for one of the practices. Complete the following audit activity in class, working with your team to process the data. We anticipate that you will work on this during the TBL workshop (on either 24th or 25th January, depending on your team). You can do the analysis any time, but we recommend making use of these sessions for the analysis as staff will be present to help with any issues. 1. Calculate the mean number of PPI issues in 12 months. 2. Calculate the mean number of alginate antacid issues in 12 months. 3. Determine the percentage of patients who order more than TWO alginate prescriptions in 12 months. Task 2: Generate an audit report Using this template, you should each produce a 1000-word report on your findings from this QIPP project, to inform staff within the practice about; 1. The current level of performance and 2. Based on the current performance level, make recommendations for future steps. Your individual report should be submitted to Canvas on the Audit Report template. Deadline 14th Feb, 11am. Some further guidance on the different sections of the report were shared in this announcement. DATA SETS (different for each TBL Team) are available below. Select the appropriate file based on your team number. Within the file, you will find a specific tab for your team. That tab contains the data you should work with. Audit Stage 2 Data Teams 1-10.xlsx Audit Stage 2 Data Teams 11-20.xlsx Audit Stage 2 Data Teams 21-30.xlsx copy to edit. 24 UNIVERSITY of BRADFORD Your audit assignment • In the workshop... Provided a data set from your practice - Working within your TBL team: 1. Calculate the MEAN number of PPI issues over 12 months 2. Calculate the MEAN number of alginate issues in the same period • Determine the PERCENTAGE of patients on PPIs who are issued >2 alginate antacids in 12 months. Feb 2022 Healthcare Professional: AUDIT Save a copy